Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years

References

• Weinstein MC, O’Brien B, Hornberger J, et al., and the ISPOR Task Force on Good Research Practices – Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling StudiesValue Health 2003;6:9-17
   Google Scholar
• Briggs A, Sculpher M. Claxton K. Decision Modelling for Health Economic Evaluation (Handbooks for Health Economic Evaluations). : Oxford University PressOxford, 2006
   Google Scholar
• Ades AE, Sculpher M, Sutton A,. et al.Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA,. et al.Prevention of venous thromboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3): 338-400S
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 1998; 3:57-60
   PubMedGoogle Scholar
• Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987;257:203-8
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kahn SR, Davidson BL,. et al.Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-96
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence website: http://www.nice.org.uk/ [Last accessed 31 March 2008]
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health website: http://www.cadth.ca/ [Last accessed 31 March 2008]
   Google Scholar
• Scottish Medicines Consortium website: http://www. scottishmedicines.org.uk/ [Last accessed 31 March 2008]
   Google Scholar
• Drummond M, Aristides M, Davies L,. et al.Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis after total hip replacement surgery. Br J Surg 1994;81:1742-6
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ 1994;150: 1083-90
   PubMed Web of Science ®Google Scholar
• Menzin J, Colditz GA, Regan MM,. et al.Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64
   PubMed Web of Science ®Google Scholar
• Borris LC, Lassen MR. Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Drugs 1996;52(Suppl 7):42-6
   PubMed Web of Science ®Google Scholar
• Abdool-Carrim T, Adler H, Becker P, . et al.The cost and benefit of prophylaxis against deep vein thrombosis in elective hip replacement. DVT/PE Prophylaxis Consensus Forum. S Afr Med J 1997;87:594-600
   PubMed Web of Science ®Google Scholar
• Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health Syst Pharm 1997;54:1185-90
   PubMed Web of Science ®Google Scholar
• Levin LA, Horst M, Bergqvist D. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery. Pharmacoeconomics 1998;13(1 pt 2): 111-18
   PubMed Web of Science ®Google Scholar
• Anderson DR, O’Brien B, Nagpal S. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1998
   Google Scholar
• Detournay B, Planes A, Vochelle N,. et al.Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998;13(1 pt 1):81-9
   PubMed Web of Science ®Google Scholar
• Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 1998;20:182-95
   PubMed Web of Science ®Google Scholar
• Nicolaides A, Bosanquet N. Cost-effectiveness of desirudin in the prevention of the thromboembolic complications of surgery. J Med Econ 1999;2:155-66
   Google Scholar
• Marchetti M, Liberato NL, Ruperto N,. et al.Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica 1999;84:730-7
   PubMed Web of Science ®Google Scholar
• Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value Health 2000; 3:397-406
   PubMedGoogle Scholar
• Levin LA, Bergqvist D. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery. Pharmacoeconomics 2001;19(5 pt 2):589-97
   PubMed Web of Science ®Google Scholar
• Botteman MF, Caprini J, Stephens JM,. et al.Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther 2002;24:1960-86
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thromb Haemost 2002;87:586-92
   PubMed Web of Science ®Google Scholar
• Nerurkar J, Wade WE, Martin BC. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy 2002;22:990-1000
   PubMed Web of Science ®Google Scholar
• Gordois A, Posnett J, Borris L,. et al.The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1:2167-74
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur J Health Econ 2003;4:254-62
   PubMedGoogle Scholar
• Honorato J, Gomez-Outes A, Navarro-Quilis A,. et al.Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 2004;22:885-94
   PubMed Web of Science ®Google Scholar
• Annemans L, Minjoulat-Rey MC, De KM,. et al.Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin Belg 2004;59:346-57
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Davidson BL, Kahn SR,. et al.A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 2004;22:605-20
   PubMed Web of Science ®Google Scholar
• Haentjens P, De GK, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 2004;124:507-17
   PubMed Web of Science ®Google Scholar
• Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs 2005;5:121-30
   PubMedGoogle Scholar
• Olsen J, Gundgaard J, Borris LC. The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark. Ugeskr Laeger 2005;167:2273-9
   PubMedGoogle Scholar
• Szucs TD, Kaiser WE, Mahler F,. et al.Thromboembolic prophylaxis with fondaparinux in major orthopaedic surgery: outcomes and costs. Heart Drug 2005;5:121-30
   Google Scholar
• Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients. Expert Rev Pharmacoecon Outcomes Res 2006;6:171-80
   PubMedGoogle Scholar
• Venous thromboembolism. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery, London: National Collaborating Centre for Acute Care, 2007. Available at: http://www.rcseng.ac.uk/surgical_research_units/nccac/guidelines/venous_thrombo_guideline.html [Last accessed 1 April 2008]
   Google Scholar
• Spruill WJ, Wade WE, Leslie RB. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery. Blood Coagul Fibrinolysis 2004;15:539-43
   PubMed Web of Science ®Google Scholar
• Spruill WJ, Wade WE, Leslie RB. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 2004;11:3-8
   PubMedGoogle Scholar
• Posnett J, Gordois A. Cost-effectiveness of fondaparinux vs enoxaparin as prophylaxis against venous thromboembolism following orthopedic surgery [abstract]. Value Health 2002; 5:444
   Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P,. et al.The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8
   Google Scholar
• Almeida JI, Coats R, Liem TK,. et al.Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998;27:309-14
   PubMed Web of Science ®Google Scholar
• 3rd annual clinical report. Hemel Hempstead: UK National Joint Registry for England and Wales, 2005. Available at: http://www.njrcentre.org.uk/documents/reports/annual/3rd/NJR_AR2_LR.pdf [Last accessed 10 July 2007]
   Google Scholar
• Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr, and the Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003;124( Suppl 6):349-56S
   Google Scholar
• Bell GK, Goldhaber SZ. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Vasc Med 2001;6:23-9
   PubMed Web of Science ®Google Scholar
• Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 2004;40:971-7
   PubMed Web of Science ®Google Scholar
• Pellegrini Jr VD, Clement D, Lush-Ehmann C,. et al.The John Charnley Award: natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 1996;333: 27-40
   PubMed Web of Science ®Google Scholar
• Elting LS, Escalante CP, Cooksley C,. et al.Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61
   PubMed Web of Science ®Google Scholar
• Garabedian-Ruffalo SM, Gray DR, Sax MJ,. et al.Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985;42:304-8
   PubMedGoogle Scholar
• Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis 1998;28(Suppl 3):8-16
   PubMedGoogle Scholar
• Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract 2000;3:179-84
   PubMedGoogle Scholar
• Anderson DR, O’Brien BJ, Levine MN,. et al.Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-12
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Kahn SR, Stumpo C,. et al.Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs 2004;4:325-33
   PubMedGoogle Scholar
• Hull RD, Pineo GF, Francis C,. et al.Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2208-15
   PubMedGoogle Scholar
• Colwell Jr CW, Pulido P, Hardwick ME,. et al.Patient compliance with outpatient prophylaxis: an observational study. Orthopedics 2005;28:143-7
   PubMed Web of Science ®Google Scholar
• Spahn G. Compliance with self-administration of heparin injections in outpatients. Eur J Trauma 2002;28:104-9
   Google Scholar
• Spyropoulos AC. Outpatient protocols for treatment of venous thromboembolism using low-molecular-weight heparin: to treat or not to treat at home. Arch Intern Med 1999;159:1139-40
   PubMed Web of Science ®Google Scholar
• Yusen RD, Haraden BM, Gage BF,. et al.Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999;115:972-9
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Jonsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis 2000;30(Suppl 2): 130-5
   PubMedGoogle Scholar
• Backman K, Carlsson P, Kentson M,. et al.Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment. Scand J Prim Health Care 2004;22:44-9
   PubMed Web of Science ®Google Scholar
• Comp PC, Spiro TE, Friedman RJ, et al., and the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A:336-45
   Google Scholar
• Ingelgard A, Hedner E, Stigendal J, et al. Patient-reported outcomes in patients with deep vein thrombosis treated with warfarin. Poster presented at the 17th International Congress on Thrombosis; Bologna, Italy. Oct 26-30, 2002
   Google Scholar
• Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36
   PubMed Web of Science ®Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997;4:49-56
   PubMed Web of Science ®Google Scholar
• O’Meara 3rd JJ, McNutt RA, Evans AT,. et al.A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330:1864-9
   PubMed Web of Science ®Google Scholar
• Robinson A, Thomson R, Parkin D,. et al.How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001;6:92-8
   PubMedGoogle Scholar
• Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74
   PubMed Web of Science ®Google Scholar
• Ziegler S, Schillinger M, Maca TH,. et al.Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. Thromb Res 2001;101:23-33
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A,. et al.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Minar E, Bialonczyk C,. et al.The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-63
   PubMed Web of Science ®Google Scholar
• Prandoni P. Risk factors of recurrent venous thromboembolism: the role of residual vein thrombosis. Pathophysiol Haemost Thromb 2003 Sep-2004 Dec;33:351-3
   PubMed Web of Science ®Google Scholar
• Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995;155:1031-7
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Prins MH,. et al.Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141:249-56
   PubMed Web of Science ®Google Scholar
• Singh H, Masuda EM. Comparing short-term outcomes of femoral-popliteal and iliofemoral deep venous thrombosis: early lysis and development of reflux. Ann Vasc Surg 2005; 19:74-9
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Turkstra F, Buller HR,. et al.Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med 2000;160:669-72
   PubMed Web of Science ®Google Scholar
• Monreal M, Martorell A, Callejas JM,. et al.Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. J Intern Med 1993; 233:233-8
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study. Am J Surg 1985;150(4A):54-63
   Google Scholar
• Lindner DJ, Edwards JM, Phinney ES,. et al.Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986;4:436-42
   PubMed Web of Science ®Google Scholar
• Franzeck UK, Schalch I, Bollinger A. On the relationship between changes in the deep veins evaluated by duplex sonography and the post-thrombotic syndrome 12 years after deep vein thrombosis. Thromb Haemost 1997;77: 1109-12
   PubMed Web of Science ®Google Scholar
• Janssen MC, Haenen JH, van Asten AW,. et al.Clinical and haemodynamic sequelae of deep venous thrombosis: retrospective evaluation after 7–13 years. Clin Sci 1997;93:7-12
   PubMed Web of Science ®Google Scholar
• McNally MA, McAlinden MG, O’Connell BM,. et al.Postphlebitic syndrome after hip arthroplasty. 43 patients followed at least 5 years. Acta Orthop Scand 1994;65:595-8
   PubMed Web of Science ®Google Scholar
• Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence, 2004. Available at: http://www.nice.org.uk/page.aspx?o=201974 [Last accessed 31 March 2008]
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE,. et al.The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91
   PubMed Web of Science ®Google Scholar